Eli Lilly (NY:LLY)

Meta Platforms Breaks Ground on Massive $10 Billion Indiana Data Center: A Giant Leap Toward 'Personal Superintelligence'

Topics Bonds ETFs Economy

February 12, 2026

On February 11, 2026, Meta Platforms Inc. (NASDAQ: META) officially broke ground on a sprawling $10 billion data center campus in Lebanon, Indiana, marking a monumental shift in the company’s...

As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying...

Topics Artificial Intelligence Earnings Economy

The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026

February 12, 2026

Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market ↗

Topics Artificial Intelligence Bonds Economy

February 12, 2026

Novo Nordisk plans to sell Wegovy in vials in the U.S., expanding options as it competes with Eli Lilly in the growing weight-loss drug market.

Via Benzinga

Healthcare’s Renaissance: Sector Outshines Tech as Policy Clarity Sparks Q4 Surge

February 12, 2026

The healthcare sector has staged a dramatic structural breakout, ending a multi-year period of relative stagnation to lead the global markets into 2026. After a powerful 10% gain in the final quarter...

Goldman Sachs Predicts 12% S&P 500 Rally in 2026: Five Key Themes for the "Marathon" Bull Market

Topics Artificial Intelligence Economy World Trade

February 12, 2026

As the global economy stabilizes into a period of disinflationary growth, Goldman Sachs (NYSE: GS) has released a robust 2026 stock market outlook, forecasting a 12% total return for the S&P 500. This...

Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗

Topics Artificial Intelligence Economy Initial Public Offering

February 12, 2026

Both companies are betting on interest in weight loss pills.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

1 Cash-Producing Stock with Competitive Advantages and 2 That Underwhelm

February 11, 2026

I Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now? ↗

February 11, 2026

Energy stocks are in the spotlight, and ExxonMobil is best in breed.

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

Topics Artificial Intelligence

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗

February 11, 2026

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

The healthcare leader looks increasingly unstoppable.

Topics Intellectual Property

3 Reasons to Buy Eli Lilly Stock ↗

February 11, 2026

Disney has hired a new CEO, with Josh D'Amaro taking over for Bob Iger in March.

Topics Government

Disney Has Its Next CEO ↗

February 11, 2026

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗

February 11, 2026

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Topics Artificial Intelligence

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

Via Finterra

Topics Economy Intellectual Property

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

February 11, 2026

This stock has been known to soar after good news.

Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong...

The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call

February 11, 2026

Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what to expect.

Topics Earnings

Zoetis (ZTS) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 10, 2026

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Topics Artificial Intelligence

Organon Earnings: What To Look For From OGN

February 10, 2026

Could these two companies be biotech giants in the making?

Topics Artificial Intelligence World Trade

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 10, 2026

These exchange-traded funds invest in some of the best growth stocks in the world.

2 Vanguard ETFs That Could Turn $400 Per Month Into $1 Million ↗

February 10, 2026

The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.

Topics ETFs

Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗

February 10, 2026

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British...

Topics Artificial Intelligence Earnings Economy

The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026

February 10, 2026

Via Finterra

Topics Artificial Intelligence Economy Fraud

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

February 10, 2026

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Today is February 10, 2026. The telehealth landscape stands at a historic inflection point, and no company better embodies this volatility than Hims & Hers Health, Inc. (NYSE: HIMS). After a meteoric...

The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS)

February 10, 2026

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know. ↗

February 10, 2026

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

Topics Intellectual Property

February 10, 2026

The stock has climbed in the triple digits over the past three years.

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect.

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

February 09, 2026